Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,147.00+2.92%ETH$2,419.90+5.43%GOLD$4,071.00+3.31%OIL$88.53-7.87%
Smart Investors Daily
SID Premium
MeiraGTx Holdings plc logo

NASDAQ · MGTX

MeiraGTx Holdings plc

Healthcare · Biotechnology

$9.52

Up+$0.01 (+0.10%)

Updated Nov 4, 2026, 6:59 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
701.08M
P/E ratio
-4.18
Dividend yield
0.00%
52-week range
$6.62 – $15.35
Volume
393.76K
Avg. volume
497.35K

Price performance · MGTX

MGTX price history

1M range · 0 trading sessions · Daily adjusted prices

MGTX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MGTX news

The latest Smart Investors Daily articles mentioning MGTX.

Stock researchCompany · Overview

MGTX research

Overview

Company profile and research snapshot.

Company profile

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
MGTX recent ratings
DateFirmRatingTarget
Sep 24, 2026Goldman SachsNeutral—
Aug 14, 2026RBC CapitalOutperform—
Jul 8, 2026RBC CapitalOutperform—
Jul 8, 2026HC Wainwright & Co.Buy—
May 15, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit three posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress, which is being held from October 27-30, 2026, in Hamburg, Germany and one poster at the Network of Excell

Yahoo · Sep 23, 2026

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most rec

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By